Literature DB >> 21270059

Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.

Ilya Kister1, Eric Chamot, Joshua H Bacon, Gary Cutter, Joseph Herbert.   

Abstract

BACKGROUND: Although the natural history of multiple sclerosis has been charted extensively, it is still not known whether the trajectory of disability accumulation has changed in the era of disease-modifying therapies (DMTs).
OBJECTIVE: The objective of this study was to examine trends in Multiple Sclerosis Severity Score (MSSS) with regard to calendar year of enrollment into the New York State MS Consortium (NYSMSC).
METHODS: Distributions of MSSS were calculated for each year of enrollment, from 1996 to 2007. Quantile regression was used in a multivariable analysis to model for conditional distribution of MSSS quantiles as functions of potential confounders.
RESULTS: The cohort consisted of 6238 patients. Mean age at enrollment was 38 years (SD=10) and mean disease duration was 10.1 years (SD=7.3); 57% were on DMTs. The quantile regression model of trends in MSSS between 1996 and 2007 controlled for age, sex, ethnicity, diagnostic delay, and disease duration and demonstrated a robust trend toward lower MSSS with increasing year of enrollment. The model-predicted median MSSS at enrollment in 1996 was 5.04 (95% CI, 4.86-5.21), and in 2007 was 3.78 (95%CI, 3.36-4.20; p<0.001). The downward trend in MSSS during the enrollment period was confirmed by analysis of Expanded Disability Status Scale (EDSS) distributions, adjusted for disease duration, in successive years of enrollment.
CONCLUSIONS: The recent enrollees into the NYSMSC had lower MSSSs compared to the earlier enrollees. The apparent slowing in disability accumulation is likely due to a complex combination of factors: advent of DMTs and improvements in MS care, as well as selection, migration, and recall biases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270059     DOI: 10.1177/1352458510396269

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  10 in total

1.  Natural history of multiple sclerosis symptoms.

Authors:  Ilya Kister; Tamar E Bacon; Eric Chamot; Amber R Salter; Gary R Cutter; Jennifer T Kalina; Joseph Herbert
Journal:  Int J MS Care       Date:  2013

2.  Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

Authors:  Omid Beiki; Paolo Frumento; Matteo Bottai; Ali Manouchehrinia; Jan Hillert
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

3.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

4.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

5.  The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration.

Authors:  Mitchell T Wallin; Ruth Whitham; Heidi Maloni; Shan Jin; Jonathan Duckart; Jodie Haselkorn; William J Culpepper
Journal:  Fed Pract       Date:  2020-04

6.  Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.

Authors:  Mohammed Aljumah; Raed Alroughani; I Alsharoqi; Saeed A Bohlega; Maurice Dahdaleh; Dirk Deleu; Khaled Esmat; Ahmad Khalifa; Mohammad A Sahraian; Miklós Szólics; Abdulrahman Altahan; Bassem I Yamout; Peter Rieckmann; Abdulkader Daif
Journal:  Mult Scler Int       Date:  2013-12-17

7.  Age Related Multiple Sclerosis Severity Score: Disability ranked by age.

Authors:  Ali Manouchehrinia; Helga Westerlind; Elaine Kingwell; Feng Zhu; Robert Carruthers; Ryan Ramanujam; Maria Ban; Anna Glaser; Stephen Sawcer; Helen Tremlett; Jan Hillert
Journal:  Mult Scler       Date:  2017-02-03       Impact factor: 6.312

8.  Pediatric Multiple Sclerosis Severity Score in a large US cohort.

Authors:  Jonathan D Santoro; Michael Waltz; Greg Aaen; Anita Belman; Leslie Benson; Mark Gorman; Manu S Goyal; Jennifer S Graves; Yolanda Harris; Lauren Krupp; Timothy Lotze; Soe Mar; Manikum Moodley; Jayne Ness; Mary Rensel; Moses Rodriguez; Teri Schreiner; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; Brigitte F Hurtubise; Shelly Roalstad; John Rose; T Charles Casper; Tanuja Chitnis
Journal:  Neurology       Date:  2020-07-20       Impact factor: 9.910

9.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

10.  Anorectal dysfunction in multiple sclerosis: a systematic review.

Authors:  Sanober Nusrat; Elsie Gulick; David Levinthal; Klaus Bielefeldt
Journal:  ISRN Neurol       Date:  2012-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.